Oncolytics Biotech Inc. ads

What if an IV immunotherapy could drive KRAS-specific immunity at the systemic level? Coming up at #ASCO26, we’ll present translational data that show pelareorep—an investigational, systemically active immunotherapy—reveals the tumor to the immune system, initiating an antiviral response that expands mutant KRAS–specific T-cell clones in blood, with clonal expansion associated with tumor volume reductions in pancreatic cancer. The findings highlight pelareorep’s depth of immune activation and reinforce its potential relevance in RAS-driven GI cancers, where new immunotherapy approaches are urgently needed.

Advances in systemically delivered immune‑activating therapies are opening new opportunities across oncology. Join our Jared Kelly and Richard Trauger along with special guests Drs. Richard Vile, Sanjay Goel, and Van Morris on May 28 for a live webinar hosted by Endpoints News. We’ll explore what’s next in viral immunotherapy, spotlighting upcoming studies in colorectal and anal cancer—two areas of significant unmet need in GI oncology—and how systemically delivered approaches are being advanced across indications.

Hear from leaders advancing next-generation GI oncology. Register to join Endpoints News for a live discussion on systemic viral immunotherapy as a backbone strategy in GI cancers, including CRC and SCAC. 📅 May 28 | 🕚 11:30–12:30 ET

I’ll be participating in an Endpoints News webinar focused on systemic viral immunotherapy and how emerging translational insights are informing clinical development in GI cancers. The discussion will bring together academic and industry perspectives on mechanism, trial design, and regulatory considerations in indications such as CRC and SCAC. 📅 May 28 | 🕚 11:30 AM–12:30 PM ET 👉 Register here: https://lnkd.in/g8E4WR84

Hear directly from leaders advancing next-generation GI oncology programs. Register today to join Endpoints News for a live discussion on systemic viral immunotherapy being positioned as a potential backbone strategy in GI oncology. This session brings together industry and academic leaders to examine how emerging clinical, translational, and regulatory insights are shaping more efficient, guidance-informed paths toward registration in indications such as colorectal cancer (CRC) and squamous cell carcinoma of the anal canal (SCAC)—and what that means for future combination strategies and partnership opportunities. You’ll hear from: • Richard G. Vile, Ph.D. (Mayo Clinic) • Sanjay Goel, M.D. (Rutgers Cancer Institute) • Van Morris, M.D. (MD Anderson Cancer Center) • Jared Kelly, CEO, Oncolytics Biotech • Richard Trauger, Ph.D., Translational Science, Oncolytics Biotech 📅 Thursday, May 28 🕚 11:30 AM–12:30 PM ET

What you’ll take away from our upcoming Endpoints News webinar: 🔹 How systemic viral immunotherapy is being positioned as a backbone strategy in GI oncology 🔹 Insight into CRC and SCAC study design and what matters for registrational decision-making and development 🔹 Perspective on how greater regulatory clarity can enable efficient development and partnering paths